Trial Profile
Phase I, Open-Label, Pharmacokinetic, Dose Escalation Study of Carisbamate in Adult and Pediatric Subjects With Lennox-Gastaut Syndrome
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 01 Jun 2023
Price :
$35
*
At a glance
- Drugs Carisbamate (Primary)
- Indications Lennox-Gastaut syndrome
- Focus Pharmacokinetics
- Sponsors SK Life Science
- 15 Dec 2022 Status changed from recruiting to completed.
- 29 Mar 2022 Planned primary completion date changed from 28 Dec 2021 to 28 Apr 2022.
- 06 Oct 2021 Planned End Date changed from 28 Jun 2021 to 28 Jun 2022.